London, United Kingdom

Matthew Copeland Catley

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2011-2015

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Matthew Copeland Catley

Introduction: Matthew Copeland Catley, based in London, GB, is an accomplished inventor with a focus on biotechnological advancements. With a total of two patents to his name, Catley's work particularly emphasizes the inhibition of the IKK-B gene, a significant area of research with implications for various diseases.

Latest Patents: Matthew Catley's latest inventions revolve around the development of compositions and methods for inhibiting the expression of the IKK-B gene. His patents describe a double-stranded ribonucleic acid (dsRNA) designed to inhibit this gene's expression. The dsRNA comprises an antisense strand that is generally 19-25 nucleotides in length and is substantially complementary to a portion of the IKK-B gene. These inventions also encompass pharmaceutical compositions that include the dsRNA along with a pharmaceutically acceptable carrier. Notably, methods for treating diseases triggered by the expression or activation of the IKK-B gene are also outlined in his patents.

Career Highlights: Matthew Catley has made significant strides in his career, working with prominent companies such as Alnylam Pharmaceuticals, Inc. and Imperial College of Science, Technology and Medicine. These positions have provided him opportunities to advance his knowledge and influence in the biopharmaceutical sector, particularly in the development of innovative therapies.

Collaborations: Throughout his career, Catley has collaborated with notable figures in the field, including Antonin de Fougerolles and Andrew Sprague. These partnerships have fostered an environment of innovation, allowing for the exchange of ideas and expertise that benefit the research community.

Conclusion: Matthew Copeland Catley stands out as a key figure in the field of biotechnology, with his innovative patents addressing critical health challenges. His work on the IKK-B gene not only demonstrates his ingenuity as an inventor but also showcases the potential for his research to impact therapeutic approaches. As he continues to build on his accomplishments, the scientific community eagerly anticipates further advancements from this London-based inventor.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…